

**22-SEP-2017 18:10
CANCER CONTROL ACCRUAL REPORT**

18:10 Friday, September 22, 2017 1

STUDY	O R P E E G N	ARM	TOTAL	REGS.	REGS.	REGS.	REGS.	REGS.	ADMIN
			REGS.	LAST Month	LAST Month	LAST Month	LAST Month	LAST Month	
S1007-Breast,Adj,N1,Endocrine+/-Chemo	1 Y 1	Recurrence Score testing	9365	777	378	172	66	15	BREAST
			9365	777	378	172	66	15	
	2 Y 2	Chemo and Endocrine Therapy	2529	257	128	57	17	5	
		3 Endocrine Therapy Alone	2518	258	124	55	20	5	
			5047	515	252	112	37	10	
S1207-Brst,Adj,Endocrine+/-Everolimus	1 Y 1	Blinded drug + Endocrine	677	213	106	45	18	5	BREAST
		2 Blinded drug + Endocrine	679	217	106	53	23	2	
			1356	430	212	98	41	7	
S1316-Compar. Effectiv. Trial for MBO	1 Y 1	Randomization Surgery	2	1	1	1	1	1	SURV
		2 Randomization Non-surgical M	1	1	1	0	0	0	
		3 Patient Choice Surgery	33	20	11	4	0	0	
		4 Patient Choice Non-surgical M	74	44	29	15	5	1	
			110	66	42	20	6	2	
S1400I-Non-Match: Nivo + Ipi vs Nivo	1 Y 1	Nivolumab + Ipilimumab	112	60	24	11	1	0	LUNG
		2 Nivolumab	117	62	28	13	7	1	
			229	122	52	24	8	1	
S1404-Melan, Adv, HD-IFN/Ipilimumab vs MK-3475	2 Y 2	FDA approved regimen	678	488	243	118	21	1	MELAN
		3 MK-3475 (Pembrolizumab)	667	484	243	110	20	0	
			1345	972	486	228	41	1	
S1415CD-TrACER CSF Standing Order Intervention for FN	1 Y 1	Site assigned to Cohort	311	311	178	84	22	6	CCD
		2 Site randomized: Control	179	179	152	81	29	5	
		3 SiteRand Int Risk: CSF	229	229	167	103	41	15	
		4 SiteRand Int Risk: No CSF	176	176	152	92	39	7	
			895	895	649	360	131	33	
S1417CD-Colorectal, Cost Cohort Study	1 Y 1	Observation	106	96	74	41	14	4	CCD
			106	96	74	41	14	4	
S1418-Breast, Adj, TNBC, MK-3475 (Pembrolizumab)	1 Y 1	Tissue for PD-L1 testing	81	81	70	43	20	4	BREAST
			81	81	70	43	20	4	
	2 Y 2	Observation	32	32	30	16	8	0	
		3 MK-3475 (Pembrolizumab)	34	34	31	18	7	2	

**22-SEP-2017 18:10
CANCER CONTROL ACCRUAL REPORT**

STUDY	O R P E E G N	ARM	REGS.					ADMIN
			TOTAL REGS.	LAST Month	LAST Month	LAST Month	LAST DAYS	
			66	66	61	34	15	2
S1501-Surv, Breast Stg IV, Card Tox w/ Carvedilol	1	Y	1	0	0	0	0	0
			1	0	0	0	0	0
	2	Y	1	0	0	0	0	0
			1	0	0	0	0	0
S1602-Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG	1	Y	1	10	9	5	2	0
		TICE BCG						GU
	2	Tokyo-172 BCG	11	11	11	8	4	2
	3	Prime + Tokyo-172 BCG	11	11	10	8	2	2
			32	32	30	21	8	4
S0820-PACES: ColrecStg0-3 Blind DFMO/Sulindac	0	Y	405	143	69	45	10	4
		Pre-Registration	405	143	69	45	10	4
	1	Y	44	18	11	2	1	0
		Blinded drug						
	2	Blinded drug	36	11	2	0	0	0
	3	Blinded drug	35	11	2	0	0	0
	4	Blinded drug	46	20	13	6	3	0
			161	60	28	8	4	0

22-SEP-2017 18:10
CANCER CONTROL ACCRUAL REPORT

Open Studies with No Registrations

S1501-Surv, Breast Stg IV, Card Tox w/ Carvedilol regtype: 1

S1501-Surv, Breast Stg IV, Card Tox w/ Carvedilol regtype: 2